Back to Results
First PageMeta Content
Pharmaceutical Benefits Scheme / Pharmaceuticals policy / Pharmacology / Medical terms / Epidemiology / Newborn screening / Screening / Serotonin–norepinephrine–dopamine reuptake inhibitor / Medical prescription / Medicine / Health / Healthcare in Australia


PBAC STAKEHOLDER MEETING OUTCOME STATEMENT NITISINONE FOR TYROSINAEMIA TYPE 1 4 February 2015 Department of Health, Canberra Attendees Members of the Pharmaceutical Benefits Advisory Committee (PBAC), clinicians with exp
Add to Reading List

Document Date: 2015-03-12 23:53:04


Open Document

File Size: 39,77 KB

Share Result on Facebook

Company

A.Menarini Australia Pty Ltd / /

Country

Australia / /

IndustryTerm

Authority applications / /

MedicalCondition

inherited metabolic diseases / metabolic diseases / disease / developmental and cognitive disorders / eye disorders / metabolic disorders / hereditary tyrosinaemia type / /

MedicalTreatment

liver transplant / /

Organization

Department of Human Services Prior Written Approval of Complex Drugs Reply Paid / Australasian Society of Inborn Errors of Metabolism / Pharmaceutical Benefits Advisory Committee / Department of Human Services / Department of Health / Metabolic Dietary Disorders Association / National Association of Testing Authorities / Therapeutic Goods Administration / /

Position

Chair / Governor / specialist physician / Dental Medical Practitioners Nurse / /

URL

http /

SocialTag